Compare HNST & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNST | SPRY |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.8M | 509.4M |
| IPO Year | 2021 | 2020 |
| Metric | HNST | SPRY |
|---|---|---|
| Price | $4.92 | $5.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $3.05 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $371,317,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | $5.93 | $81.64 |
| P/E Ratio | $55.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.07 | $4.91 |
| 52 Week High | $5.84 | $15.09 |
| Indicator | HNST | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 38.03 |
| Support Level | $3.22 | $4.91 |
| Resistance Level | $5.84 | $8.61 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 57.74 | 52.73 |
The Honest Co Inc is a personal care company dedicated to creating cleanly-formulated and sustainably-designed products for everyone from babies to adults. By combining thoughtful design with science-based innovation, the company delivers personal care products for everyone from babies to adults, spanning categories across wipes, personal care, diapers, and beauty. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.